$ News

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Insider Ups Holding By 36% During Year

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Kronos Bio announces interim CEO and workforce cuts of 83%

Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Kronos mulls ‘strategic alternatives’ after axing cancer drug development

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio announces preclinical data from p300 KAT inhibitor program

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to present data from p300 KAT inhibitor program

Piper Sandler Remains a Buy on Kronos Bio (KRON)

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease